GlaxoSmithKline's Andrew Witty

GlaxoSmithKline CEO Andrew WittyAndrew Witty - GlaxoSmithKline

Total Compensation: $2.68M

Details: Witty has spent his entire career at GSK. In 2007, the industy vet's loyalty was rewarded when he was promoted from head of the European pharma unit to CEO following Dr. Jean-Pierre Garnier's retirement. The CEO beat out a number of other company veterans vying for the spot, including Chris Viehbacher--who later left to head Sanofi-Aventis. Witty officially took the reigns in May of 2008 and for just 6 months at the helm, he was awarded £1.78 million--or $2.68 million. At the time of his succession, Witty's base salary was set at $1.28 million; he received just over $1 million, plus a $1.5 million bonus.

GSK News:
GSK chief elaborates on biotech strategy
NICE snubs Glaxo's pay-for-performance plan
GlaxoSmithKline to axe 850 jobs in R&D
GSK to cut 1,800 U.S. pharma reps
GSK's Witty opts out of generics market
Witty: Diversifying and derisking GSK

GlaxoSmithKline's Andrew Witty

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.